There has never been a better time to buy GlaxoSmithKline plc, Persimmon plc and Admiral Group plc

GlaxoSmithKline plc (LON: GSK), Persimmon plc (LON: PSN) and Admiral Group plc (LON: ADM) are growing companies that produce a high income.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

If you are investing in shares, what do you look for? Well, I would say a key component is growth: increasing revenues and increasing earnings. And I would expect that a substantial proportion of those earnings to be paid out as dividends, leading to a high income for the stock.

So here I have picked three companies that have prospects for growth and a high dividend yield. One is a pharmaceutical company, one is a house builder, and the third  is an insurance firm, and I think there has never been a better time to buy all 3.

Treading water

In the 1980s, I remember people talking about chemical company ICI as a barometer for British industry. If Britain did well, then so did ICI.

I feel a similar way about pharma giant GlaxoSmithKline (LSE: GSK) today. Its share price movements have tracked those of the FTSE 100, almost as if the index and the firm were running a 3-legged race.

During the torrid bear market of the past 16 years, GSK, like the FTSE 100, has been treading water, some times moving a little up, some times moving a little down. But as the next great bull market gradually gets underway, I expect this firm to rise, just as the FTSE 100 will.

A 2016 P/E ratio of 16.61 shows the stock is reasonably priced, and their is a dividend yield of 5.49% that adds to GSK’s appeal.

Unbeatable combination

Britain’s economy has recovered strongly, and this has led to a resurgent housing market. That’s why I have long advocated investing in house builders such as Persimmon (LSE: PSN). After the dark night of the Credit Crunch, house builder share prices have been recovering strongly. And yet you can still buy in at bargain prices.

Persimmon’s 2016 P/E ratio is predicted to be just 11.11, with a dividend yield of 5.19%. This is an unbeatable combination of growth and income, and I think this company would be a worthy addition to your portfolio.

Highly cash generative

The insurance industry, once seen as unexciting, has undergone a series of revolutions. Firstly, as phone-based insurance took over from traditional brokers, and then as online insurance firms and price comparison sites have grabbed much of the business.

Admiral Group (LSE: ADM) is one of the leading price comparison and online insurance companies worldwide, owning brands such as confused.com, Admiral and Diamond in the UK, as well as websites in Europe and North America.

This promises to be a fast growing area, as Admiral’s international businesses follow the lead from the UK, which has perhaps the most advanced insurance market in the world. And this company is well placed to take advantage.

That’s why Admiral’s share price has been trending steadily upwards, and a 2016 P/E ratio of 19.05 may seem fully priced, but the well-covered dividend yield of 5.01% shows that this is a highly cash generative firm that has bright long-term prospects.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »